• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • News
  • Lifestyle
  • Wellness
  • Cuisine
  • Product Reviews
  • Subscribe
Cannabis News and Culture Magazine

Cannabis News and Culture Magazine

Cannabis News and Culture Magazine

Emerald Media News Subscription
  • Print Magazines
  • 100+ Minority-Owned Companies to Support
  • No Pipe, No Problem
  • Blunt vs. Joint
  • The Cost of Cannabis in Each State
  • Calculating Your Edibles Dosage
  • Flintts Mouthwatering Mints

Endexx Announces Investment in EcoHealth Neuropathy Inc.

September 13, 2018 by Emerald Media Group Leave a Comment

This information was provided by irthcommunications.com

Send your Press Release here.

Targeting Multi-Billion-Dollar Market for Pain Relief Treatment for Diabetic Neuropathy Patients

CAVE CREEK, AZ, Sept. 12, 2018 – Endexx Corporation (OTC PINK: EDXC), a provider of innovative phytonutrient-based food and nutritional products, has announced its investment in EcoHealth Neuropathy, Inc., an Arizona-based corporation, to launch its platform for clinical and technology driven management of neuropathies.

EcoHealth Neuropathy Inc., a full-service healthcare provider for the treatment of diabetic neuropathy will be led by Dr. Daniel Kiddy, Endexx’s Chief Medical Officer.  Dr. Kiddy, will help build and manage the health practice and design compliance and standard operating procedures for the utilization of natural plant-based medicine in the treatment of neuropathy patients.

CEO Todd Davis commented, “Endexx looks to lead the standardization of government compliance, as well as, collaborate with state educational institutions in Arizona. We will be establishing best practices and procedures for plant-based alternative medicine in support of traditional medical practices. In addition, podiatric care physicians will be the first targeted roll-out for the patient treatment, utilizing phyto-nutrients as alternative medicine. This is a tremendous market opportunity, as the diabetic neuropathy market is set to reach $5.7 billion by 2024.”

Dr. Daniel Kiddy stated, “After four years of case study observation of patients utilizing phyto-cannibidiol for the reduction of pain, Endexx and EcoHealth Neuropathy will establishment a scientific platform to conduct clinical trials and collect data that can be peer evaluated and published over time, leading to a strong alternative for the treatment of pain and neuropathy versus opiate based pain management.”

About Endexx

Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites® is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 – the m3hub and the AutoSpense™. Both products provide essential solutions to promote regulatory compliance and full accountability. The AutoSpense™ is a commercial-grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, AutoSpense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.endexx.com and www.phytobites.com.

Safe Harbor Notice

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.

Filed Under: Press Release Tagged With: Press

Reader Interactions

Leave a Reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube

Advertise Here

Categories

Sustainability

seaweed naturals

SeaWeed Naturals Combines the Power of Seaweed with Cannabis to Further Ocean Restoration

April 3, 2022 By Maggie Horton

fungi climate change

Research Finds Fungi Help Ease Climate Change and Benefit the Environment

March 30, 2022 By Julia Meyer

climate crisis and the pandemic

“We Can Act:” What Bending the COVID-19 Curve Teaches Us About the Climate Crisis

April 21, 2020 By Melissa Hutsell

Footer

  • Subscribe
  • About
  • Contact
  • Privacy
  • Press

Recent

  • Up in Smoke: An Interview with Smoke Proper, the Trailblazing Cannabis Accessory Brand
  • Priscilla Vilchis and Lil Kim Launch Aphrodisiak: A Cannabis Brand Focused on Sensuality, Social Justice, and Inclusivity
  • First Latina CEO of a Cannabis Company Partners with Music Industry Trailblazer Lil Kim to Launch Aphrodisiak Brand
  • Aphrodisiak: The New Female-Led Cannabis Brand Empowering Women and Promoting Inclusivity
  • Las Vegas Welcomes Aphrodisiak

Search

Copyright © 2023 · The Emerald™ · News & Lifestyle Magazine

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Cannabis News and Culture Magazine
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.